A Neoadjuvant Study of Abemaciclib (LY2835219) in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Hormone Receptor Positive Tumor|Early-Stage Breast Carcinoma
Interventions: DRUG: Abemaciclib|DRUG: Loperamide|DRUG: Anastrozole
Sponsor: Eli Lilly and Company